Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

Sarah Cannon Cancer Center, Nashville, TN, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Nashville, TN
Treatments:ChemotherapyHospital:Sarah Cannon Cancer Center
Drugs:Journal:Link
Date:Apr 2005

Description:

Patients: This Phase II study involved 52 women with stage II or IV ovarian cancer. The median age was 57. None of the patients had received first-line chemotherapy before the study.

Treatment: The treatment consisted of three chemotherapeutic agents: paclitaxel, carboplatin, and etoposide.

Toxicity: Grade 3-4 toxicities included leukopenia, thrombocytopenia, peripheral neuropathy, arthralgia/myalgia, and fatigue.

Results: Although the overall median survival for the entire patient population was not determined, patients with suboptimal tumor debulking had a median survival of 24 months.

Support: Bristol-Myers Squibb provided financial support for this study. Bristol-Myers Squibb manufactures and markets paclitaxel, carboplatin, and etoposide.

Correspondence: John D. Hainsworth





Back